Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

155.95USD
5:16pm BST
Change (% chg)

$-0.04 (-0.03%)
Prev Close
$155.99
Open
$156.43
Day's High
$156.88
Day's Low
$154.31
Volume
24,193
Avg. Vol
190,965
52-wk High
$183.96
52-wk Low
$128.58

Select another date:

Fri, Jul 13 2018

U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.

U.S. court denies Jazz Pharma bid to revive patents on narcolepsy drug

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals Inc to launch a generic version of the medicine.

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

UPDATE 2-Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Jazz Pharmaceuticals to settle U.S. probe for $57 million

BOSTON, May 8 Jazz Pharmaceuticals plc on Tuesday said that it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

BRIEF-Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98

* JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Jazz Pharma Submits Supplemental New Drug Application For Xyrem To Treat Cataplexy And Excessive Daytime Sleepiness In Pediatric Narcolepsy Patients

* JAZZ PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

Select another date: